Prof Randy Mrsny
Profile
Randall Mrsny obtained a BS degree in Biochemistry and Biophysics and a PhD degree in Anatomy and Cell Biology from the University of California at Davis undergraduate and medical school campuses, respectively. As an NIH post-doctoral fellowship he studies membrane lipid-protein interactions at the Institute of Molecular Biology located in the University of Oregon Eugene campus. Prior to taking Professors’ post in Cardiff University and now the University of Bath, Randy led research groups in two companies: ALZA and Genentech. He has been involved in starting two new biotech companies through the acquisition of venture capital funding. Randy has been elected president of an international society and organized international meeting. He currently serves as a reviewer or advisor for multiple international agencies and companies.
Research Interests
The current research interest of the Mrsny Laboratory focuses on a variety of aspects of epithelial cell structure/function in health and disease. This work is supported through grants from governmental agencies and private foundations as well as through collaborative partnership with pharmaceutical companies.
- Identification of molecules secreted by intestinal and airway epithelial cells which can control neutrophil and eosinophil transmigration
- Identification of molecules that allow epithelial cells regulation to lymphocyte activation
- Examine the role played by tight junction elements in controlling epithelial cells oncogenesis
- Examine endogenous mechanisms that dynamically control tight junction opening and closing for drug delivery
- Examine epithelial transcytosis mechanisms used by bacterial toxins for the delivery of biotherapeutics such as proteins, peptides, and siRNA.
Publications
Zhang, H., Jiao, W., Sun, L., Fan, J., Chen, M., Wang, H., Xu, X., Shen, A., Li, T., Niu, B., Ge, S., Li, W., Cui, J., Wang, G., Sun, J., Fan, X., Hu, X., Mrsny, R., Hoffman, A. R. and Hu, J.-F., 2013. Intrachromosomal looping is required for activation of endogenous pluripotency genes during reprogramming. Cell Stem Cell, 13 (1), pp. 30-35.
Liu, K., Hearne, K., Mrsny, A., Staka, C. and Mrsny, R. J., 2012. A strategy to improve selectivity and targeting to epithelial-derived cancer cells. Journal of Controlled Release, 164 (2), pp. 205-212.
Mrsny, R. J., 2012. Oral drug delivery research in Europe. Journal of Controlled Release, 161 (2), pp. 247-253.
Daugherty, A. L., Rangell, L. K., Eckert, R., Zavala-Solorio, J., Peale, F. and Mrsny, R. J., 2011. Sustained release formulations of rhVEGF165 produce a durable response in a murine model of peripheral angiogenesis. European Journal of Pharmaceutics and Biopharmaceutics, 78 (2), pp. 289-297.
Brayden, D. J. and Mrsny, R. J., 2011. Oral peptide delivery: Prioritizing the leading technologies. Therapeutic Delivery, 2 (12), pp. 1567-1573.
Lipp, R., Mrsny, R. and Park, K., 2010. Seventh international nanomedicine and drug delivery symposium (NanoDDS'09). Journal of Controlled Release, 146 (2), p. 163.
Daugherty, A. L. and Mrsny, R. J., 2010. Local tissue distribution and cellular fate of vascular endothelial growth factor (VEGF) following intramuscular injection. Journal of Drug Targeting, 18 (1), pp. 27-35.
Sharma, V. K., Chih, H. W., Mrsny, R. J. and Daugherty, A. L., 2009. The formulation and delivery of monoclonal antibodies. In: An, Z., ed. Therapeutic Monoclonal Antibodies: From Bench to Clinic. Hoboken, NJ: Wiley, pp. 671-705.
Mrsny, R. J., 2009. Lessons from nature: "Pathogen-Mimetic" systems for mucosal Nano-medicines. Advanced Drug Delivery Reviews, 61 (2), pp. 172-192.
Mrsny, R. J., 2009. Metabolic processes at injection sites affecting pharmacokinetics, pharmacodynamics and metabolism of protein and peptide therapeutics. In: Mrsny, R. J. and Daugherty, A. L., eds. Proteins and Peptides: Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes. New York: Informa Healthcare, pp. 80-105.
Ward, S. G. and Mrsny, R. J., 2009. New insights into mechanisms of gastrointestinal inflammation and cancer. Current Opinion in Pharmacology, 9 (6), pp. 677-679.
Mrsny, R. J. and Daugherty, A. L., eds., 2009. Proteins and Peptides: Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes. New York: Informa Healthcare.
Pazos, M., Siccardi, D., Mumy, K. L., Bien, J. D., Louie, S., Shi, H. N., Gronert, K., Mrsny, R. J. and McCormick, B. A., 2008. Multidrug resistance-associated transporter 2 regulates mucosal inflammation by facilitating the synthesis of hepoxilin A3. The Journal of Immunology, 181 (11), pp. 8044-8052.
Mrsny, R. J., Brown, G. T., Gerner-Smidt, K., Buret, A. G., Meddings, J. B., Quan, C., Koval, M. and Nusrat, A., 2008. A key claudin extracellular loop domain is critical for epithelial barrier integrity. American Journal Of Pathology, 172 (4), pp. 905-915.
Feighery, L. M., Cochrane, S. W., Quinn, T., Baird, A. W., O’Toole, D., Owens, S.-E., O’Donoghue, D., Mrsny, R. J. and Brayden, D. J., 2008. Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro. Pharmaceutical Research, 25 (6), pp. 1377-1386.
